Teprotumumab for treating thyroid eye disease and thyroid dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the clinical outcomes of patients with active thyroid eye disease who exhibit significant symptoms such as proptosis, pain, and diplopia. Patients recommended for treatment with teprotumumab infusion will be assessed by an oculoplastic surgeon and an endocrinologist. The study aims to monitor the effects of teprotumumab on the symptoms and progression of thyroid eye disease, which is a debilitating autoimmune condition affecting the eyes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* only DOD beneficiaries
* adult patients 18 years of age or older
* adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease

Exclusion Criteria:

* Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
* patients with a history of uncontrolled diabetes mellitus
* patients with a history/diagnosis of uncontrolled inflammatory bowel disease
* patients under age 18 years
* patients who are pregnant or trying to become pregnant.

Where it's running

• Walter Reed National Military Medical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Thanh D Hoang, DO — Walter Reed National Military Medical Center
• Study coordinator: Thanh D Hoang, Do
• Email: thanh.d.hoang.mil@health.mil
• Phone: 3012955165

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• AI-based MRI and ultrasound for thyroid-related eye disease

  This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Huangpu District · NCT07716397

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• Links between inflammation, thyroid antibodies, and retinal changes in Graves disease

  This study will see if blood markers of inflammation and thyroid antibodies are linked to retinal measurements from OCT in adults with Graves disease and in healthy adults.

  Recruiting Elazıg Fethi Sekin Sehir Hastanesi · Elâzığ, Elaziğ · NCT07480720

• Teprotumumab N01 for adults with thyroid eye disease

  This will try Teprotumumab N01 in adults with recent-onset thyroid eye disease to see if it reduces eye inflammation and improves vision and quality of life.

  Recruiting Peking University Third Hospital · Beijing · NCT07423013

• Teprotumumab N01 vs IV steroids for active thyroid eye disease

  This trial tests whether teprotumumab N01 can help people with active thyroid eye disease better than intravenous steroids.

  Recruiting Phase 4 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07265258

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.